Altimmune shares slide as the FDA flashes a red light for the IND work on their intranasal Covid-19 vaccine
The FDA has ordered Altimmune $ALT to hit the brakes on their shift into the clinic with an intranasal Covid-19 vaccine.
The biotech says that the agency has fairly benign intentions, maintaining that regulators halted the IND application so they could get certain protocol modifications and additional CMC data. This is, however, the first time the agency has put up a red light for a vaccine developer.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
